Author:
Hazawa Masaharu,Takahashi Kenji,Wada Koji,Mori Takao,Kawahara Norio,Kashiwakura Ikuo
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference22 articles.
1. Foroutan B, Ruf AA, Costall B, Anderson D (2007) An in vitro model to study chemoresistance in non-Hodgkin’s lymphoma patients over-expressing mutant p53. J Pharmacol Toxicol Methods 55:151–158
2. Jazirehi AR, Gan XH, Vos D, Emmanouilides C, Bonavida B (2003) Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin’s lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2:1183–1193
3. Johnston JS, Johnston A, Wientjes MG, Au JL (2003) Synergy between 3′-azido-3′- deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res 20:957–961
4. Stewart FM, Temeles D, Lowry P, Thraves T, Grosh WW, Quesenberry PJ (1993) Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation. Blood 81:2283–2289
5. White CA (1991) Rituximab immunotherapy for non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 14:241–250
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献